Executive Summary: ISG Provider Lens® Medical Devices Digital Services - U.S. 2026
05 Oct 2026
The individual quadrant reports are available at:
Shift toward AI-enabled models integrating engineering, regulatory, quality and post-market functions
This study assesses the evolving U.S. medical device digital services landscape, focusing on providers supporting integrated capabilities across the product lifecycle. It examines how service providers are advancing digital engineering, regulatory compliance, quality management, cybersecurity and post-market operations as software-defined, connected and AI-enabled devices expand. The assessment also considers providers’ ability to operationalize AI responsibly, address emerging regulatory requirements and enable integrated, digitally driven lifecycle models at enterprise scale.
Market context
The U.S. medical device industry is moving from product-centric development toward software-defined, connected and continuously evolving product ecosystems. Software, cloud platforms, embedded intelligence and Internet of Medical Things (IoMT) connectivity are becoming integral to device functionality, while manufacturers increasingly extend products through companion applications, remote monitoring and digital services. This shift is changing the economics of the product lifecycle: engineering increasingly continues after commercialization as manufacturers manage software releases, cybersecurity vulnerabilities, device performance and fielddriven product improvements across large installed bases.
Regulatory change is reinforcing this transition. The FDA’s Quality Management System Regulation (QMSR), cybersecurity expectations, Software Bill of Materials (SBOM) requirements and evolving oversight of AI- and ML-enabled Software as a Medical Device (SaMD) are increasing the need for traceability across requirements, risks, software, testing and post-market changes. Compliance is consequently becoming a continuous lifecycle discipline, requiring closer integration among engineering, quality, regulatory affairs and cybersecurity rather than documentation and validation concentrated around submission milestones.
AI is accelerating this convergence, but the market is moving beyond experimentation. GenAI and agentic AI are being applied to software development, verification and validation, regulatory documentation, quality processes, complaint handling and lifecycle impact assessment. However, regulated adoption requires human oversight, validation, auditability and defensible governance, making production readiness more important than the number of AI use cases demonstrated.
At the same time, connected devices are creating larger volumes of real-world and operational data. Manufacturers are increasingly seeking to convert this data into Real-world evidence (RWE), predictive quality, remote service intelligence and productperformance insights. As these capabilities mature, the boundaries between engineering, regulatory compliance and post-market operations are becoming less distinct, creating demand for integrated digital foundations that support continuous product improvement throughout the medical device lifecycle.
Enterprise priorities
U.S. medical device manufacturers are recalibrating digital investment around integrated lifecycle outcomes rather than isolated technology programs. Enterprises increasingly prefer providers that can connect product engineering, regulatory affairs, quality management, cybersecurity and post-market operations while maintaining accountability across the product lifecycle. This reflects the growing interdependence of these functions: a software update can affect validation evidence, cybersecurity posture, regulatory documentation and field performance simultaneously. Buyers, therefore, value partners that can reduce functional handoffs, preserve traceability and support coordinated change across complex product portfolios.
Engineering productivity remains a major priority. As manufacturers manage large installed bases, legacy architectures and growing software complexity, engineering productivity remains a major priority. Enterprises are applying AI and automation to requirements engineering, software development, testing, verification and validation (V&V), traceability and technical documentation. However, the emphasis is shifting from individual productivity gains toward reducing end-to-end development and sustenance cycle times. Reusable engineering assets, digital threads, cloud-native platforms and automated impact assessment are gaining importance as manufacturers seek rapid product updates without increasing compliance risk.
Continuous compliance and cybersecurity are becoming embedded lifecycle requirements. Organizations are modernizing Quality Management Systems (QMS), strengthening SBOM management and integrating regulatory, risk and cybersecurity controls directly into engineering workflows. QMSR readiness is reinforcing demand for harmonized quality processes, while connected and software-driven devices require stronger vulnerability management and lifecycle traceability. Buyers increasingly expect regulatory and quality transformation to improve engineering velocity rather than operate as a downstream control function.
Production-ready AI is another critical buying criterion. Enterprises are moving beyond PoC and evaluating whether AI-enabled workflows can operate reliably within regulated environments. Validation, explainability, audit trails, data governance, human oversight and change control increasingly influence purchasing decisions. Agentic AI is attracting interest, but manufacturers remain selective about autonomous execution in safety- or compliance-critical processes.
Finally, enterprises are prioritizing connected products and post-market intelligence. Remote patient monitoring, IoMT connectivity, predictive maintenance, complaint intelligence and Real-world data (RWD) are increasingly expected to generate actionable feedback for engineering, quality and regulatory teams. Manufacturers want to convert field information into RWE, earlier safety signals and product improvements rather than maintain disconnected post-market repositories. Across these priorities, buyers are increasingly evaluating providers on measurable outcomes, including rapid releases, lower validation effort, improved quality, reduced complaint cycle times and greater device uptime, making lifecycle performance a more important differentiator than technology deployment alone.
Provider dynamics
Digital engineering and product development: From engineering capacity to lifecycle acceleration
The competitive benchmark in digital engineering is moving beyond the ability to provide large engineering teams. Most established providers can support embedded software, cloud development, connected devices, V&V and product sustenance. What increasingly separates leading providers is how effectively they combine these capabilities to shorten regulated product-development and modernization cycles.
AI is becoming embedded across requirements analysis, coding, testing, traceability, impact assessment and documentation, with providers increasingly developing medtechspecific engineering platforms and reusable components. Sustenance engineering is also receiving greater attention as manufacturers look to modernize large installed product portfolios without undertaking costly redesigns. Digital twins, simulation, automated testing and device-to-cloud architectures are helping to address this challenge.
The strongest providers combine software expertise with hardware, firmware, mechanical and systems engineering, supported by physical laboratories and validation infrastructure. Connected-device engineering is also expanding toward interoperability with clinical systems and cloud platforms. As these capabilities become more common, differentiation will increasingly depend on reusable regulated engineering intellectual property, measurable productivity improvements and the ability to connect engineering changes directly with quality and regulatory evidence.
Regulatory compliance, strategy and quality assurance: Toward continuous compliance
The regulatory services market is moving away from document-intensive, milestonebased support toward continuous compliance embedded within the product lifecycle. Submission preparation, technical documentation, Quality Management System (QMS) support and validation remain essential, but these capabilities alone provide less differentiation than in previous years.
Providers are investing heavily in regulatory intelligence, AI-assisted authoring, automated traceability, audit preparation and quality analytics. GenAI and agentic AI are increasingly being used to compare changing regulations, draft documents, generate test artifacts and support complaint and Corrective and Preventive Action (CAPA) workflows. However, production maturity varies considerably, making validation, human oversight and auditability important points of separation.
Leading providers are also connecting regulatory change more directly with engineering. This allows manufacturers to understand which products, requirements, risks, tests and documentation may be affected when regulations or product designs change. Strategic regulatory expertise remains important, particularly for complex FDA pathways and AI-enabled devices. The market is therefore beginning to separate providers that primarily automate regulatory work from those that combine regulatory strategy, digital quality and lifecycle intelligence.
AI and innovation driving post-market enablement: From processing events to preventing them
Post-market services are undergoing the most visible change. Traditional complaint processing, field service and surveillance remain important, but providers are increasingly applying AI to determine why quality and performance issues occur and how they can be prevented. Complaint platforms are becoming more intelligent, combining omnichannel intake, classification, investigation support, reportability assessment, CAPA linkage and regulatory reporting. Connected-device platforms are adding remote diagnostics, predictive maintenance and installed-base intelligence, while remote patient monitoring and patient engagement are bringing manufacturers closer to real-world product use.
More advanced provider propositions connect device telemetry, complaints, service information, manufacturing data and clinical signals to create feedback loops into engineering and quality. RWD is also becoming important as manufacturers seek to generate RWE and understand product performance outside controlled environments.
The next competitive frontier is therefore closed-loop lifecycle intelligence: detecting a field signal, understanding its quality and regulatory implications, identifying the affected product or component and feeding that insight back into engineering. Providers that can demonstrate this model in regulated production environments will increasingly separate themselves from those focused primarily on post-market process automation.
Outlook
Lifecycle integration becomes the baseline
Over the next five years, the U.S. medical device digital services market will move further toward integrated lifecycle models, where engineering, regulatory, quality, cybersecurity and postmarket operations share common data and workflows. Capabilities that differentiate providers today, AI-assisted engineering, automated traceability, connected-device platforms and digital quality, will increasingly become standard expectations. Buyers will place greater value on providers that can demonstrate how these capabilities work together to improve lifecycle performance.
AI moves deeper into regulated workflows
AI adoption will progress from productivity assistance toward more agentic execution, but autonomy will advance unevenly. Documentation, testing, regulatory intelligence, complaints and sustenance are likely to scale faster than safety-critical decisions. As adoption grows, validation, explainability, auditability, model monitoring and human oversight will become fundamental requirements. The next frontier will be the convergence of operational AI with AI embedded directly within regulated products.
Post-market becomes a product improvement engine
Connected devices will generate richer streams of operational, clinical and patient data, making post-market intelligence increasingly important to product strategy. Manufacturers will expect providers to connect complaints, telemetry, service history and RWD with engineering and quality processes, enabling earlier risk detection, predictive maintenance and stronger RWE.
Ultimately, competitive differentiation will shift from technology breadth toward measurable lifecycle outcomes. Providers that can demonstrate rapid product updates, lower validation effort, continuous compliance, fewer quality issues and improved installedbase performance will be best positioned as manufacturers consolidate relationships around strategic lifecycle partners.
Access to the full report requires a subscription to ISG Research. Please contact us for subscription inquiries.
Page Count: 14
Categories
QUESTIONS?
To purchase this product or for more information, please contact your account manager: